Pipeline

November 12, 2018

Company	Drug/Device	Medical Condition	Status
AVEO Oncology	Tivozanib	Highly refractory advanced or metastatic renal cell carcinoma (RCC)	Met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS) in Phase III clinical trial
Fortis Therapeutics, Inc.	FOR46	Metastatic castration-resistant prostate cancer and late-stage multiple myeloma	The FDA has cleared two Investigational New Drug (IND) applications
Shoulder Innovations	InSet Humeral Short Stem System	Degenerative, rheumatoid or traumatic arthritis in the shoulder	Received 510(k) clearance from the FDA
Eli Lilly	Trulicity (dulaglutide)	Heart attacks and stroke in type 2 diabetes	Reduced major adverse cardiovascular events (MACE) in REWIND Phase III clinical trial
Themis Bioscience	MV-CHIK	Chikungunya fever	Primary endpoint —neutralizing antibodies after one or two injections — was met in Phase II clinical trial
Bristol-Myers Squibb	Empliciti (elotuzumab)	Multiple myeloma in adults who have received at least two prior therapies	Granted approval by the FDA
Bone Therapeutics	PREOB	Hip osteonecrosis (ON)	Halted Phase III trial after interim analysis showed it would not meet endpoints
Endo International plc	Collagenase clostridium histolyticum (CCH)	Cellulite	Positive results announced from two identical Phase III RELEASE* clinical trials
Mallinckrodt plc	H.P. Acthar Gel	Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU)	First patient screened in company's Phase IV, multi-center, multiple-dose, open label trial to assess effect
OncoSec Medical	TAVO™ (in combination with Merck's KEYTRUDA®)	Late-stage triple negative breast cancer (TNBC)	First patient treated in KEYNOTE-890 Phase II clinical trial
Glenmark Pharmaceuticals	CD38xCD3 bispecific antibody GBR 1342	Solid tumors	Launching a Phase I clinical trial
BD	LUTONIX® 014 Drug-Coated Balloon (DCB) IDE	Narrowed or obstructed arteries below the knee	Primary safety and efficacy endpoints were met in Phase I clinical trial
Urovant Sciences, Inc.	Vibegron	Overactive bladder	Completed enrollment in international Phase III clinical trial, EMPOWUR to evaluating safety and efficacy